Evidence map›Paper›PMID 41126784›Full record

ReviewThe Kaohsiung journal of medical sciences2026

Nanotechnology in Skin Cancer Therapy: Recent Progress in Targeted Delivery.

Huang-Ping Yu, Ching-Yun Hsu, Jia-You Fang, Zih-Chan Lin

Abstract readReview
In one paragraph

Review in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Huang-Ping YuDepartment of Anesthesiology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
Ching-Yun HsuDepartment of Nutrition and Health Sciences, Chang Gung University of Science and Technology, Taoyuan, Taiwan.
Jia-You FangDepartment of Anesthesiology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
Zih-Chan LinChronic Diseases and Health Promotion Research Center, Chang Gung University of Science and Technology, Chiayi, Taiwan.

Funding

Chang Gung Memorial Hospital CMRPG3P0721-3Chang Gung University of Science and Technology ZRRPF6N0011
6 · The paper itself

Abstract

Skin cancer, encompassing melanoma and non-melanoma types, remains a significant public health concern globally. Conventional therapies-such as surgery, radiotherapy, chemotherapy, and immunotherapy-are constrained by poor skin penetration, systemic toxicity, and high recurrence rates. Nanotechnology has emerged as a promising strategy to address these limitations through enhanced drug delivery, targeted tumor accumulation, and reduced off-target effects. This review summarizes recent advances in nanocarrier-based approaches for skin cancer therapy. Key platforms include liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, and biomimetic systems. These nanocarriers facilitate passive, active, and stimuli-responsive targeting, thereby improving drug distribution within tumors and enhancing therapeutic precision. Applications include chemotherapy, photothermal and photodynamic therapy, gene and RNA delivery, and immunotherapy. Despite substantial preclinical success, challenges persist in translating findings to the clinic. These include limited dermal penetration, tumor heterogeneity, immune clearance, and regulatory barriers. Innovative solutions-such as multifunctional nanocarriers, personalized formulations, and non-invasive delivery devices-are being investigated to address these issues. In conclusion, nanotechnology holds considerable potential to transform skin cancer treatment. Continued interdisciplinary efforts are crucial for translating laboratory innovations into clinically viable therapies, ensuring safer and more effective outcomes for patients.

Indexed as

Drug Delivery SystemsNanotechnologySkin NeoplasmsAnimalsAntineoplastic AgentsDrug CarriersHumansImmunotherapyLiposomesNanoparticlesPhotochemotherapyAntineoplastic AgentsDrug CarriersLiposomesanticancer drugdrug targetingnanocarriernanomedicineskin cancer

Identifiers

PMID41126784
PMCPMC12782258

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.